SCHEMBL7977957

SCHEMBL7977957

Cc1ccc(-c2[nH]c(-c3cnc4ccccc4c3)nc2C(=O)O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.51
TOP2B Q02880 1/20 0.51
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
HPGD P15428 2/20 0.48
MEN1 O00255 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
KMT2A Q03164 1/20 0.48
PIN1 Q13526 3/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MGAM O43451 1/20 0.44
MITF O75030 1/20 0.44
XBP1 P17861 1/20 0.44
PAX8 Q06710 1/20 0.44
KLF5 Q13887 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7991852 0.86 KDM4E (0.44) TOP2ATOP2BKDM4EALDH1A1HPGD
SCHEMBL7977763 0.84 CTRC (0.53) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7978027 0.82 KDM4E (0.67) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7989231 0.80 RAB9A (0.47) KDM4EALDH1A1HPGDMEN1GAA
SCHEMBL7977705 0.76 DHODH (0.54) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7977738 0.75 MAPK14 (0.56) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7992039 0.75 MAPK14 (0.56) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7991805 0.75 KDM4E (0.48) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL7989975 0.74 DHODH (0.61) KDM4EALDH1A1HPGDMEN1GLA
SCHEMBL23555381 0.73 PDGFRB (0.66) KDM4EALDH1A1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130165472-A1 HETEROARYLS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-06-27 US disclosed
US-6288061-B1 INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS WELFIDE CORPORATION (JP) 2001-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165472-A1 HETEROARYLS AND USES THEREOF PIK3R4, VPS4B, PIK3C2A TOP2A 2542/4885TOP2B 1241/4885KDM4E 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.